Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 645 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Controlled Human Infection Clear all
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

NCT00419263
View directory record Official record
Conditions
Influenza
Interventions
Peramivir 150 mg, Peramivir 300 mg, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
58
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

NCT05933525
View directory record Official record
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

NCT00510874
View directory record Official record
Conditions
Influenza
Interventions
Pumarix™, Pandemrix ™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

NCT05047770
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su, Flu D-QIV, mRNA-1273
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
46
States / cities
Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

PRO 140 by IV Administration in Adults With HIV-1 Infection

NCT00613379
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Highly active antiretroviral treatment (HAART)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

NCT06799741
View directory record Official record
Conditions
DENV-3 Controlled Human Infection Model
Interventions
AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

NCT04789577
View directory record Official record
Conditions
Influenza, Human
Interventions
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
8
States / cities
Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

NCT01573312
View directory record Official record
Conditions
Influenza
Interventions
ASO3 Adjuvant, Influenza A/H5N1 Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 4, 2026, 12:09 PM EDT
Recruiting Not applicable Interventional

The Effects of Endotracheal Suctioning on Pain and Serum Markers

NCT06692400
View directory record Official record
Conditions
Intensive Care Unit ICU, Intubation, Critical Illness, Mechanical Ventilation, Pain Measurement, Pain, Procedural, Oxidative Stress, Hypoxia, Biomarkers / Blood, Adult, Uric Acid, Sepsis, COVID, Influenza, Pneumonia
Interventions
endotracheal tube suctioning
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 4, 2026, 12:09 PM EDT
Terminated Phase 1 Interventional

A Trial of NT-I7 in COVID-19 (SPESELPIS)

NCT04501796
View directory record Official record
Conditions
COVID-19
Interventions
Double-Blind NT-I7, Double-Blind Placebo
Drug
Lead sponsor
NeoImmuneTech
Industry
Eligibility
19 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Not applicable Interventional Results available

The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

NCT01009645
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Fact Only Education Message, Fact and Myth Educational Message, Fact, Myth, Why Educational Message, Control Educational Message
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

NCT03969212
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 64 Years
Enrollment
4,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 4, 2026, 12:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

NCT06891066
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects

NCT00618839
View directory record Official record
Conditions
Third Degree Burn, Burns, Wound Infection, Degloving Injury
Interventions
StrataGraft Skin Tissue, Cadaver allograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

NCT04439695
View directory record Official record
Conditions
Influenza
Interventions
Low dose, Intermediate dose, High dose, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Results available

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

NCT01277601
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

NCT06134648
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection, Healthy Volunteers, Human Metapneumovirus
Interventions
RSV/hMPV vaccine candidate Dose L, RSV/hMPV vaccine candidate Dose A, RSV/hMPV vaccine candidate Dose B, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
10
States / cities
Los Alamitos, California • Los Angeles, California • Rolling Hills Estates, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

NCT02282215
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Infection
Interventions
CLT-008, G-CSF
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules

NCT01259453
View directory record Official record
Conditions
Hepatitis B
Interventions
Vaccination to prevent hepatitis B virus infection
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
3
States / cities
Hartford, Connecticut • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Sep 4, 2026, 12:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

NCT00122681
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Cervarix™, Havrix™-based investigational formulation
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
18,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 4, 2026, 12:09 PM EDT